Visfatin is a newly discovered adipocyte hormone. Recent studies showed a possible relationship between diabetes mellitus and visfatin level. But the effect of visfatin on the insulin resistance was not well understood. The aim of the present study was to explore the relation of visfatin with insulin resistance in patients with prediabetes and diabetes.
We included a total of 128 persons in the study and of these 128 persons, 36 were diabetic, 69 were prediabetic (impaired fasting glucose and impaired glucose tolerance patients) and the remaining 23 were healthy (control). In all cases, HbA1c, microalbuminuria, fasting blood visfatin, insulin, glucose, lipid profiles, fibrinojen, BUN, creatinine and CRP levels were calculated and recorded. HOMA-IR scores were calculated.The results were evaluated statistically.
According to our results visfatin levels were not different between groups (11.5±2.5 for control group; 12.1±2.7 for pre-diabetes group and 11.2±2.8 for diabetes group). Furthermore neither HOMA-IR nor other laboratory parameters (CRP, HbA1c, BMI etc.) were correlated with visfatin levels in any group. Also obesity, hiperlipidemi and gender differences did not effect on the plasma visfatin levels.
Our investigation demonstrates that visfatin has no effect on insulin resistance in type 2 diabetes. Further research is required to investigate its role in insulin resistance and the investigations of the metabolic role of visfatin may be shifted to other areas.
25 - 29 Apr 2009
European Society of Endocrinology